Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat vs ESA for sarcopenia in hemodialysis patients
ChiCTR2500106730Phase 4Not yet recruiting
- Sponsor
- Department of Nephrology, Tianjin Medical University General Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of roxadustat in anemia of renal disease, Sarcopenia, end-stage kidney disease (ESKD) and 1 more (2 arms), sponsored by Department of Nephrology, Tianjin Medical University General Hospital. Primary endpoints: hemoglobin and muscle mass. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
roxadustat
03
Conditions
anemia of renal diseaseSarcopeniaend-stage kidney disease (ESKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500106730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106730.